Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04203160
Title	Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	University of Michigan Rogel Cancer Center
Indications	biliary tract cancer intrahepatic cholangiocarcinoma extrahepatic bile duct carcinoma distal biliary tract carcinoma gallbladder carcinoma
Therapies	Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 10 of 10 entries

Facility	City	State	Zip	Country	Details
Allegheny Health Network	Pittsburgh	Pennsylvania	15224	United States	Details
Atlantic Health System	Morristown	New Jersey	07960	United States	Details
Fred Hutch/University of Washington Cancer Consortium	Seattle	Washington	98109	United States	Details
Northwestern University -- Lurie Comprehensive Cancer Center	Chicago	Illinois	60611	United States	Details
University Hospitals - Seidman Cancer Center	Cleveland	Ohio	44106	United States	Details
University of Arizona Cancer Center	Tucson	Arizona	85724	United States	Details
University of Michigan Rogel Cancer Center	Ann Arbor	Michigan	48109	United States	Details
University of Texas Southwestern -- Simmons Comprehensive Cancer Center	Dallas	Texas	75390	United States	Details
University of Wisconsin - Carbone Cancer Center	Madison	Wisconsin	53705	United States	Details
Vanderbilt-Ingram Cancer Center	Nashville	Tennessee	37232	United States	Details

Showing 1 to 10 of 10 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field